Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Timothy P Hughes, David M Ross, Junia V Melo.
    Summary: This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1?2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria.

    Contents:
    Epidemiology and risk factors.- Pathophysiology.-Diagnosis
    Management of patients with CML
    Challenges of treatment: treatment-resistant CML
    Useful resources for your patients and caregivers.
    Digital Access Springer 2014
  • Other
    Lamandier, Esther; Guillaume; Peter; Moine; Peter; Peire Vidal; Bernart; Folquet; Riquier, Giraut; Gherardello; Lorenzo.
    Contents:
    Dame vostre doulz viaire : virelai ; Dou mal qui m'a longuement : virelai ; Foy porter, honneur garder : virelai ; J'aim la flour de valour : lay / Guillaume de Machault
    O starker Got / Peter von Aberg
    Kum senfter Trost / Moine de Salzbourg
    Maria gnuchtig / Peter von Sachsen
    Pos tornatz sui / Peire Vidal
    Can l'herba fresch'e / B. de Ventadour
    En chantan / Folquet de Marseille
    Jhesu Crist / Guiraut Riquier
    Per tropo fede / anonyme
    I' vo'bene / Gherardellus de Florentia
    Non vedi tu amor / L. Masii de Florentia
    Lucente stella / anonyme.
    Print p1987
  • Article
    Heybach JP, Brown PA, Vernikos-Danellis J.
    Neuroendocrinology. 1979;28(4):273-80.
    The normal diurnal variation in plasma corticosterone (COR) was abolished and the response to ether stress was enhanced at 3 days following the production of medial forebrain bundle (MFB) lesions in male rats. However, by 7 days following surgery, basal plasma COR levels and the response to ether stress appeared normal. These alterations and subsequent recovery of pituitary-adrenal activity were accompanied by decreasing hypothalamic synaptosomal uptake of serotonin (5HT) and increasing synaptosomal uptake of dopamine (DA), evident at 3 and continuing at 7 days following the lesion. Uptake of norepinephrine (NE) was not affected at 3 days but showed a reduction at 7 days following surgery. The results suggest that disruption of ascending 5HT and NE fibers to the hypothalamus can alter pituitary-adrenal activity but that normal activity recovers by 7 days following the lesion. The correlation between recovery of pituitary-adrenal activity and increases in the normal uptake of hypothalamic DA suggest that DA may interact with 5HT and NE systems in the normal control of adrenocorticotrophin (ACTH) release.
    Digital Access Access Options